Recent Articles from Business Wire

Metropolitan Commercial Bank (“MCB” or the “Bank”), a full-service commercial bank headquartered in New York City, is proud to announce that it has been Certified™ by Great Place To Work® for the second year in a row, reaffirming the Bank's commitment to fostering an exceptional workplace culture where employees feel valued, supported, and empowered to succeed.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented positive Phase 2 data for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The data were shared in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

FedEx Corp. (NYSE: FDX) today announced the appointment of Jamere Jackson as chief financial officer, effective Nov. 30. He succeeds Claude Russ, who has served as interim CFO since June 1.

The holidays should be about making memories, not making compromises. But with budgets stretched, busy schedules and growing shopping lists, customers are looking for ways to make the season special without added stress. Walmart is making it easier with three major holiday shopping events from November 12 through December 2, bringing savings on gifts, seasonal favorites and everyday essentials – plus a new holiday marketing campaign.

Genius Sports Limited (“Genius Sports”) (NYSE:GENI) today announced that it will release its third quarter 2026 results before 8:00AM ET on Thursday, November 5, 2026.

Braemar Hotels & Resorts Inc. (NYSE: BHR) (“Braemar” or the “Company”) today announced that its Board of Directors (the “Board”) intends to nominate eight highly qualified, seasoned leaders for election at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The slate of eight director candidates includes seven new, highly qualified and independent director nominees:

Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab for first-line (1L) treatment of recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC). In the 1L combination arm, treatment with petosemtamab plus pembrolizumab achieved a median overall survival (OS) of 28.2 months, associated with an overall response rate (ORR) of 63% and median progression free survival (mPFS) of 9.0 months in efficacy-evaluable patients (n=43), including a complete response (CR) rate of 19%. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain.

Jack in the Box Inc. (NASDAQ: JACK) today announced that it will report fourth quarter and full-year fiscal 2026 financial results after market close on Wednesday, December 9, 2026.

RyCarma Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for skeletal muscle diseases, today announced that the first patient was dosed in a Phase 2 clinical trial of surlorian in patients with RYR1-related myopathy (RYR1-RM).

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027.

First Farmers and Merchants Corporation (OTCID: FFMH), the holding company for First Farmers and Merchants Bank, today announced its results for the third quarter of 2026, reflecting continued growth and profitability, including robust 24.4% annualized loan growth, a 12.7% increase in net income, and an eleventh consecutive quarter of net interest margin expansion.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18 abstracts, including three oral presentations, add to the growing support for Renasight, Natera’s genetic test for CKD.

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-reported outcomes from the Phase 3 RINGSIDE trial in patients with progressing desmoid tumors and three posters providing further analyses of varegacestat’s clinical profile.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new two-year follow up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P).

More than 300 broadcasters, radio personalities, artists, and content creators from Spanish-language media and entertainment gathered at St. Jude Children's Research Hospital® on Oct. 9-10 for the Promesa y Esperanza® seminar. The two-day event is part of the Music Gives to St. Jude Kids® program that unites music lovers and artists behind the mission of St. Jude.

Bidgely congratulates partner Pacific Power for receiving the 2026 Association of Edison Illuminating Companies (AEIC) Achievement Award. The recognition honors the utility’s strategic use of artificial intelligence (AI) and data analytics to identify, reach and protect vulnerable customers across Oregon and California.

Alliance Resource Partners, L.P. (NASDAQ: ARLP) (“we,” “us,” “our,” “ARLP” or the “Partnership”) today reported financial and operating results for the three and nine months ended September 30, 2026 (the “2026 Quarter” and “2026 Period,” respectively). This release includes comparisons of results to the three and nine months ended September 30, 2025 (the “2025 Quarter” and “2025 Period,” respectively) and to the quarter ended June 30, 2026 (the “Sequential Quarter”).

D-Wave Quantum Inc. (NASDAQ: QBTS), (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software, and services, today announced that management will be participating in the following investor conferences:

Builders FirstSource (NYSE: BLDR) today announced that its 2026 charity event raised approximately $1.6 million for Blood Cancer United. This marks the 20th year of the Builders FirstSource partnership with Blood Cancer United, which has helped raise more than $19 million for critical research, patient support, and advocacy programs dedicated to advancing treatments and cures for blood cancers over those two decades.

Adults and children facing cancer will have access to more advanced treatment options close to home as the AdventHealth Cancer Institute introduces proton therapy. The MEVION S250-FIT™ Proton Therapy System will expand the care available to Central Floridians.

AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced that it intends to issue its fourth quarter and full year fiscal 2026 earnings results after the U.S. market closes on November 16, 2026. The Company will also host a conference call and webcast with analysts and investors on November 17, 2026, at 8 a.m. Eastern Time / 7 a.m. Central Time, during which management will present the Company's financial results and outlook, strategic accomplishments, and market and business trends.

Ferguson Enterprises Inc. (NYSE: FERG) announces today that it will issue its third quarter results on Monday, November 9, 2026. The results will be available on Ferguson’s website at corporate.ferguson.com at 6:45 a.m. ET.

Bank of Hawai‘i Corporation (NYSE: BOH) (the “Company”) today reported diluted earnings per common share of $1.49 for the third quarter of 2026, compared with $1.47 during the linked quarter. Net income for the quarter was $64.3 million, up 0.7% from the linked quarter. The return on average common equity for the third quarter of 2026 was 15.38% compared with 15.47% during the linked quarter.

Jacobs (NYSE: J) plans to release its fiscal fourth quarter and full year 2026 earnings results after market close on Monday, Nov. 23, 2026, and will host a conference call at 4:30 p.m. ET, during which management will make a presentation focusing on the company’s results and operating trends.

Babcock & Wilcox Enterprises, Inc. (NYSE:BW) (B&W or the “Company”) will host a conference call and webcast on Monday, November 9, 2026 at 5 p.m. ET.

Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, today announced its results of operations for the quarter ended September 30, 2026.

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training.

Casey’s (Nasdaq: CASY), the nation’s third largest convenience retailer and fifth-largest pizza chain, today announces that its first-ever pan pizza, featuring a fluffy, golden-brown square crust and edge-to-edge toppings, will arrive on its menu beginning Wednesday, Oct. 28.

KKR & Co. Inc. (NYSE: KKR) today announced that Brian J. Lee has been appointed to the Board of Directors effective October 26, 2026. His appointment will bring the number of independent directors to eight out of a total of twelve Board seats.

Maven today announced a shift from legal meeting intelligence to AI-powered matter intelligence, with plans to connect matter documents, meeting records, and legal research in one platform. Client access is planned to begin in early 2027.

Seagate Technology (NASDAQ: STX) today announced a new interoperability milestone designed to simplify high-capacity storage expansion as AI and cloud workloads drive continued data growth.

Ridge Security, a leader in AI-powered offensive security and continuous security validation, has been included in four cybersecurity technology categories across three Gartner research reports, we believe it’s reflecting the growing focus on validating security defenses and identifying exposure before attackers can exploit it.

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced new analyses from its global Phase 2 clinical trial (AP101-02) evaluating the company's Phase 3-ready lead program, AP-101, in patients with sporadic ALS and superoxide dismutase 1 (SOD1)-ALS. The new findings demonstrate greater preservation of body weight in patients treated with AP-101 compared with placebo. Weight loss has been associated with shorter survival, while longitudinal changes in weight may reflect several aspects of disease progression, including nutritional status, metabolic changes, and muscle loss.

Sable Offshore Corp. (the “Company”) (NYSE: SOC) today announced that it plans to release its third quarter 2026 financial and operating results before the market opens on Monday, November 9, 2026. The Company will host a conference call and webcast to discuss the results on the same day at 11:00 a.m. Eastern Time (10:00 a.m. Central Time).

Doug Bergeron, a significant shareholder of Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) with beneficial ownership, collectively with his affiliates and associates, of approximately 5.2% of Ethan Allen’s outstanding common stock, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that Ethan Allen shareholders vote on the WHITE universal proxy card “FOR” ALL FIVE of his highly qualified director nominees to the Board of Directors (the “Board”) – Douglas G. Bergeron, Anna Brockway, Kristine E. Miller, Steve Oblak, and Stefanie Tsen Ward – at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on November 4, 2026.

Tutor Perini Corporation (NYSE: TPC) (the “Company”), a leading civil, building and specialty construction company, announced today that it will host a conference call at 2:00 PM Pacific Time on Wednesday, November 4, 2026, to discuss the Company's third quarter 2026 results.

Atom Therapeutics, an innovative clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical trial evaluating lingdolinurad (ABP-671), for treatment of chronic kidney disease (CKD) with hyperuricemia. This Phase 2 clinical trial is being conducted in Australia and China.

DHI Group, Inc. (NYSE: DHX) ("DHI" or the "Company") today announced that it will report financial results for its third quarter ended September 30, 2026 on Wednesday, November 4, 2026, after the close of the market. Art Zeile, President and Chief Executive Officer, and Greg Schippers, Chief Financial Officer, will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results.

Joe Amara Executive Search has been selected by a large independent power producer to lead a confidential search for a Head of Power Origination. The executive will lead commercial strategy across a national wind, solar, and battery storage portfolio, with a central focus on attracting large-load customers and negotiating complex, long-term power agreements.

Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has promoted Virginie Pelletier to Head of Executive & Professional Liability (E&P) in France.

Geogentia today launched Perimeter, threat monitoring for schools, organizations, family offices, public figures and places of worship. Perimeter finds threats posted online and sends an alert that says how serious each one is and exactly what to do about it.

Honeywell Technologies (NASDAQ: HON) has announced the launch of Forge Plant Cognition, an industrial AI platform built with NVIDIA AI and accelerated computing capabilities, and Dell Technologies’ AI infrastructure. The platform is designed to help refining, petrochemical and Liquefied Natural Gas (LNG) operators generate greater value from their existing assets and transform plant operations.

PixVerse and OpenAI announced Prompt to Production, a collaborative educational initiative designed to help people and teams using AI in their creative workflows. The initiative will show participants how to combine OpenAI frontier models and agentic capabilities with PixVerse’s multimodal generation tools.

SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01 (NCT06382116) study evaluating izalontamab brengitecan (iza-bren), an investigational, first-in-class, dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus platinum-based chemotherapy (PBC) in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) who were previously treated with an EGFR tyrosine kinase inhibitor (TKI). Results will be presented today in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2026 Annual Congress taking place October 23 – 27 in Madrid, Spain, and simultaneously published in The Lancet.

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that results from the Phase 1b clinical trial of LYT-200 were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. LYT-200 is a first-in-class monoclonal antibody targeting galectin-9, an important oncogenic driver and potent immunosuppressor. It is being advanced by PureTech's Founded Entity, Gallop Oncology (Gallop).

American Hospital Dubai ("AHD"), one of the Middle East's premier private healthcare providers and a member of the Mayo Clinic Care Network, and HEI Global Health ("HEI"), a global healthcare technology and consulting company, today announced a strategic partnership to jointly build and implement RevOptix™, HEI's AI-powered Revenue Cycle and Patient Accounting Intelligence Platform, while establishing American Hospital Dubai as the inaugural Alpha Partner for the solution.

L&T Technology Services (BSE: 540115, NSE: LTTS), announced it has established a five-year contract with Nokia to support engineering and R&D activities in India. This collaboration brings together LTTS’ engineering capabilities with Nokia’s telecommunications technology work.

Alpaca, a global leader in agent-first brokerage and clearing infrastructure, today announced that its entity, Alpaca Clearing & Custody ME Ltd (“Alpaca Middle East”), has received in-principle approval (IPA) from the Financial Services Regulatory Authority (FSRA) of ADGM, the international financial centre of Abu Dhabi, in respect of its application for a Financial Services permission.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Csquare, Inc. (“Csquare” or “the Company”) (NYSE: CSQR) for violations of the securities laws.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TTM Technologies, Inc. (“TTM” or “the Company”) (NASDAQ: TTMI) for violations of the securities laws.

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (“EAI”) ecosystem company, today announced that this week’s Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 26.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Celsius Holdings, Inc. (NASDAQ: CELH) between February 21, 2025 and June 3, 2026. Celsius describes itself as a company that “develops, processes, manufactures, markets, sells, and distributes products including energy drinks.”

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) in Madrid, Spain.

Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy.

Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005). Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below). No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable. These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026. Hims describes itself as a company that “operates a health and wellness platform that connects consumers to licensed healthcare professionals.”

Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors. With longer follow-up, most of the previously unconfirmed objective responses were subsequently confirmed, reinforcing the consistency of the clinical activity observed across treatment settings. The updated analyses reinforce the depth and durability of responses observed in both 1L and 2L treatment settings and support the ongoing global Phase 3 development program. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery (neoadjuvant) in patients with solid tumors. The results were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. Xencor also reported additional follow-up data supporting selection of 400 mcg/kg as the intravenous proposed recommended Phase 3 dose and outlined plans for potential registration-enabling development by the end of 2027.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced promising preliminary clinical data from the ongoing Phase 1 monotherapy portion of its Phase 1/2 PROSPER trial evaluating FMC-376, a KRAS G12C ON+OFF inhibitor, in patients with advanced KRAS G12C-mutant solid tumors, focused on non-small cell lung cancer (NSCLC). The findings were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in CCC Intelligent Solutions Holdings Inc. (“CCC” or “the Company”) (NASDAQ: CCC) for potential breaches of fiduciary duty on the part of its directors and management.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of common stock of Papa John’s International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026. Papa Johns describes itself as a “global chain pizza company that both operates and franchises restaurants in North America and various international markets.”

Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today in an oral presentation at IDWeek 2026 in Washington, D.C.1

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SoundThinking, Inc. (NASDAQ: SSTI) to Transom Capital Group for $8.00 per share in cash, and one non-transferable contingent value right worth up to $3.00 per share.

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment with IMFINZI plus platinum chemotherapy (investigator’s choice of carboplatin or cisplatin) and etoposide.

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had refused cisplatin-based chemotherapy. Patients in the comparator arm had a radical cystectomy (surgery to remove the bladder) with or without approved adjuvant treatment.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Harte Hanks, Inc. (NASDAQ: HHS) to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing.

New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical Trials Group at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), NUBEQA® (darolutamide), to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday, October 24, at 16:30 CEST/10:30 am ET).

Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla.

Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need.

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise.

CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with newly diagnosed, checkpoint-inhibitor-naïve muscle-invasive bladder cancer (MIBC). Visugromab is a humanized monoclonal antibody designed to neutralize the tumor-derived cytokine GDF-15, a key mediator of immune suppression and resistance to anti-PD-(L)1 therapies.